Clinical response to adalimumab treatment in patients with moderate to severe psoriasis

Double-blind, randomized controlled trial and open-label extension study

Kenneth B. Gordon, Richard G. Langley, Craig Leonardi, Darryl Toth, M. Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim, Jianhua Zhong, Rebecca Hoffman, Martin M. Okun

Research output: Contribution to journalArticle

Abstract

Background: Tumor necrosis factor is pivotal in the pathogenesis of psoriasis. Adalimumab is a fully human monoclonal immunoglobulin G 1 antibody that neutralizes tumor necrosis factor. Objectives: We sought to assess the efficacy and safety of adalimumab in patients with moderate to severe plaque psoriasis. Methods: In this multicenter, randomized, double-blind, placebo-controlled study, 147 patients received adalimumab (40 mg every other week or 40 mg/wk) or placebo. After 12 weeks of blinded therapy, patients taking adalimumab could continue their assigned dosages in a 48-week extension trial; patients taking placebo were switched to adalimumab (40 mg every other week). Results: At week 12, 53% of patients taking adalimumab every other week, 80% of patients taking adalimumab weekly, and 4% of patients taking placebo achieved 75% improvement in Psoriasis Area and Severity Index score (P <.001). Responses were sustained for 60 weeks. No new safety signals were noted compared with the existing adalimumab clinical safety database. Limitations: The study was insufficiently powered to detect rare adverse events associated with adalimumab. Conclusions: Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks.

Original languageEnglish (US)
Pages (from-to)598-606
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume55
Issue number4
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Psoriasis
Randomized Controlled Trials
Placebos
Therapeutics
Safety
Tumor Necrosis Factor-alpha
Adalimumab
Immunoglobulin G
Databases
Antibodies

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis : Double-blind, randomized controlled trial and open-label extension study. / Gordon, Kenneth B.; Langley, Richard G.; Leonardi, Craig; Toth, Darryl; Menter, M. Alan; Kang, Sewon; Heffernan, Michael; Miller, Bruce; Hamlin, Regina; Lim, Liberata; Zhong, Jianhua; Hoffman, Rebecca; Okun, Martin M.

In: Journal of the American Academy of Dermatology, Vol. 55, No. 4, 10.2006, p. 598-606.

Research output: Contribution to journalArticle

Gordon, KB, Langley, RG, Leonardi, C, Toth, D, Menter, MA, Kang, S, Heffernan, M, Miller, B, Hamlin, R, Lim, L, Zhong, J, Hoffman, R & Okun, MM 2006, 'Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study', Journal of the American Academy of Dermatology, vol. 55, no. 4, pp. 598-606. https://doi.org/10.1016/j.jaad.2006.05.027
Gordon, Kenneth B. ; Langley, Richard G. ; Leonardi, Craig ; Toth, Darryl ; Menter, M. Alan ; Kang, Sewon ; Heffernan, Michael ; Miller, Bruce ; Hamlin, Regina ; Lim, Liberata ; Zhong, Jianhua ; Hoffman, Rebecca ; Okun, Martin M. / Clinical response to adalimumab treatment in patients with moderate to severe psoriasis : Double-blind, randomized controlled trial and open-label extension study. In: Journal of the American Academy of Dermatology. 2006 ; Vol. 55, No. 4. pp. 598-606.
@article{a33f152deaed4a3d8615407028f3682c,
title = "Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study",
abstract = "Background: Tumor necrosis factor is pivotal in the pathogenesis of psoriasis. Adalimumab is a fully human monoclonal immunoglobulin G 1 antibody that neutralizes tumor necrosis factor. Objectives: We sought to assess the efficacy and safety of adalimumab in patients with moderate to severe plaque psoriasis. Methods: In this multicenter, randomized, double-blind, placebo-controlled study, 147 patients received adalimumab (40 mg every other week or 40 mg/wk) or placebo. After 12 weeks of blinded therapy, patients taking adalimumab could continue their assigned dosages in a 48-week extension trial; patients taking placebo were switched to adalimumab (40 mg every other week). Results: At week 12, 53{\%} of patients taking adalimumab every other week, 80{\%} of patients taking adalimumab weekly, and 4{\%} of patients taking placebo achieved 75{\%} improvement in Psoriasis Area and Severity Index score (P <.001). Responses were sustained for 60 weeks. No new safety signals were noted compared with the existing adalimumab clinical safety database. Limitations: The study was insufficiently powered to detect rare adverse events associated with adalimumab. Conclusions: Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks.",
author = "Gordon, {Kenneth B.} and Langley, {Richard G.} and Craig Leonardi and Darryl Toth and Menter, {M. Alan} and Sewon Kang and Michael Heffernan and Bruce Miller and Regina Hamlin and Liberata Lim and Jianhua Zhong and Rebecca Hoffman and Okun, {Martin M.}",
year = "2006",
month = "10",
doi = "10.1016/j.jaad.2006.05.027",
language = "English (US)",
volume = "55",
pages = "598--606",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical response to adalimumab treatment in patients with moderate to severe psoriasis

T2 - Double-blind, randomized controlled trial and open-label extension study

AU - Gordon, Kenneth B.

AU - Langley, Richard G.

AU - Leonardi, Craig

AU - Toth, Darryl

AU - Menter, M. Alan

AU - Kang, Sewon

AU - Heffernan, Michael

AU - Miller, Bruce

AU - Hamlin, Regina

AU - Lim, Liberata

AU - Zhong, Jianhua

AU - Hoffman, Rebecca

AU - Okun, Martin M.

PY - 2006/10

Y1 - 2006/10

N2 - Background: Tumor necrosis factor is pivotal in the pathogenesis of psoriasis. Adalimumab is a fully human monoclonal immunoglobulin G 1 antibody that neutralizes tumor necrosis factor. Objectives: We sought to assess the efficacy and safety of adalimumab in patients with moderate to severe plaque psoriasis. Methods: In this multicenter, randomized, double-blind, placebo-controlled study, 147 patients received adalimumab (40 mg every other week or 40 mg/wk) or placebo. After 12 weeks of blinded therapy, patients taking adalimumab could continue their assigned dosages in a 48-week extension trial; patients taking placebo were switched to adalimumab (40 mg every other week). Results: At week 12, 53% of patients taking adalimumab every other week, 80% of patients taking adalimumab weekly, and 4% of patients taking placebo achieved 75% improvement in Psoriasis Area and Severity Index score (P <.001). Responses were sustained for 60 weeks. No new safety signals were noted compared with the existing adalimumab clinical safety database. Limitations: The study was insufficiently powered to detect rare adverse events associated with adalimumab. Conclusions: Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks.

AB - Background: Tumor necrosis factor is pivotal in the pathogenesis of psoriasis. Adalimumab is a fully human monoclonal immunoglobulin G 1 antibody that neutralizes tumor necrosis factor. Objectives: We sought to assess the efficacy and safety of adalimumab in patients with moderate to severe plaque psoriasis. Methods: In this multicenter, randomized, double-blind, placebo-controlled study, 147 patients received adalimumab (40 mg every other week or 40 mg/wk) or placebo. After 12 weeks of blinded therapy, patients taking adalimumab could continue their assigned dosages in a 48-week extension trial; patients taking placebo were switched to adalimumab (40 mg every other week). Results: At week 12, 53% of patients taking adalimumab every other week, 80% of patients taking adalimumab weekly, and 4% of patients taking placebo achieved 75% improvement in Psoriasis Area and Severity Index score (P <.001). Responses were sustained for 60 weeks. No new safety signals were noted compared with the existing adalimumab clinical safety database. Limitations: The study was insufficiently powered to detect rare adverse events associated with adalimumab. Conclusions: Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks.

UR - http://www.scopus.com/inward/record.url?scp=33748936662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748936662&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2006.05.027

DO - 10.1016/j.jaad.2006.05.027

M3 - Article

VL - 55

SP - 598

EP - 606

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -